$ZNTL

2 theses

bullish 100%neutral 0%bearish 0%

Avg return (1y)

—

Win rate (1y)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Oct 21, 12:15 PM ET

$ZNTLr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 45d ago31 prior · 63% at 3mo

Long ZNTL

10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.

Azenosertib (rapid oral) for platinum-resistant ovarian cancer showed ~35% response rate in Cyclin E1-positive patients, with DENALI overall survival data at ESMO Oct 23. Author held at $4.84 in August; down 18% to $3.99 with ±75% implied volatility.

At post $4.03Now $2.43-39.8% since postedas of Oct 21, 12:15 PM ET

1d—

3d-10.9%

1w-13.2%

1m-36.7%

3m—

6m—

1y—

original post →

$ZNTLr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 78d ago31 prior · 63% at 3mo

10 penny biotechs I'm watching for August 2026, and adding slowly

Zentalis Pharmaceuticals' azenosertib (WEE1 inhibitor) has Oct 2023 data in platinum-resistant ovarian cancer. Options pricing at ±106% implied move suggests elevated volatility; the company carries sufficient runway to reach and beyond the catalyst.

At post $4.95Now $2.43-51.0% since postedas of Oct 21, 12:15 PM ET

1d+1.0%

3d-14.7%

1w-13.3%

1m-19.4%

3m—

6m—

1y—

original post →

End of results.